Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 167

1.

Alectinib in untreated anaplastic lymphoma kinase-positive non-small cell lung cancer.

Ruppert AM, Mignard X, Wislez M.

Ann Transl Med. 2017 Dec;5(23):460. doi: 10.21037/atm.2017.09.05. No abstract available.

2.

Outcome of EGFR-mutated NSCLC patients with MET-driven resistance to EGFR tyrosine kinase inhibitors.

Baldacci S, Mazieres J, Tomasini P, Girard N, Guisier F, Audigier-Valette C, Monnet I, Wislez M, Pérol M, Dô P, Dansin E, Leduc C, Leprieur EG, Moro-Sibilot D, Tulasne D, Kherrouche Z, Labreuche J, Cortot AB.

Oncotarget. 2017 Oct 9;8(62):105103-105114. doi: 10.18632/oncotarget.21707. eCollection 2017 Dec 1.

3.

[Hot topics in 2017 in oncology and hematology. A selection by the editorial board of Bulletin du Cancer].

Vignot S, André T, Caux C, Bouleuc C, Evrard S, Gonçalves A, Lacroix M, Magné N, Massard C, Mazeron JJ, Orbach D, Rodrigues M, Thariat J, Wislez M, L'Allemain G, Bay JO.

Bull Cancer. 2018 Jan;105(1):6-14. doi: 10.1016/j.bulcan.2017.11.006. Review. French.

PMID:
29269176
4.

[Lung cancer in HIV-infected patients].

Domblides C, Canellas A, Wislez M, Fallet V, Antoine M, Crequit P, Cadranel J, Lavolé A.

Bull Cancer. 2018 Jan;105(1):111-119. doi: 10.1016/j.bulcan.2017.11.002. Epub 2017 Dec 22. Review. French.

PMID:
29269175
5.

Membrane-bound full-length Sonic Hedgehog identifies cancer stem cells in human non-small cell lung cancer.

Leprieur EG, Tolani B, Li H, Leguay F, Hoang NT, Acevedo LA, Jin JQ, Tseng HH, Yue D, Kim IJ, Wislez M, Wang C, Jablons DM, He B.

Oncotarget. 2017 Oct 10;8(61):103744-103757. doi: 10.18632/oncotarget.21781. eCollection 2017 Nov 28.

6.

Nonsmall cell lung cancer from HIV-infected patients expressed programmed cell death-ligand 1 with marked inflammatory infiltrates.

Domblides C, Antoine M, Hamard C, Rabbe N, Rodenas A, Vieira T, Crequit P, Cadranel J, Lavolé A, Wislez M.

AIDS. 2018 Feb 20;32(4):461-468. doi: 10.1097/QAD.0000000000001713.

PMID:
29194117
7.

Pro-tumoural CXCL10/CXCR3-A autocrine loop in invasive mucinous lung adenocarcinoma.

Duruisseaux M, Rabbe N, Antoine M, Vieira T, Poulot V, Cadranel J, Wislez M.

ERJ Open Res. 2017 Mar 31;3(1). pii: 00047-2016. doi: 10.1183/23120541.00047-2016. eCollection 2017 Jan.

8.

[Toward new modalities of surveillance in lung cancer patients?]

Domblides C, Chaabane N, Wislez M.

Bull Cancer. 2017 Sep;104(9):703-704. doi: 10.1016/j.bulcan.2017.07.004. Epub 2017 Aug 8. French. No abstract available.

PMID:
28801133
9.

Role of atmospheric pollution on the natural history of idiopathic pulmonary fibrosis.

Sesé L, Nunes H, Cottin V, Sanyal S, Didier M, Carton Z, Israel-Biet D, Crestani B, Cadranel J, Wallaert B, Tazi A, Maître B, Prévot G, Marchand-Adam S, Guillot-Dudoret S, Nardi A, Dury S, Giraud V, Gondouin A, Juvin K, Borie R, Wislez M, Valeyre D, Annesi-Maesano I.

Thorax. 2018 Feb;73(2):145-150. doi: 10.1136/thoraxjnl-2017-209967. Epub 2017 Aug 10.

PMID:
28798214
10.

EGFR tyrosine kinase inhibitors versus chemotherapy in EGFR wild-type pre-treated advanced nonsmall cell lung cancer in daily practice.

Tomasini P, Brosseau S, Mazières J, Merlio JP, Beau-Faller M, Mosser J, Wislez M, Ouafik L, Besse B, Rouquette I, Debieuvre D, Escande F, Westeel V, Audigier-Valette C, Missy P, Langlais A, Morin F, Moro-Sibilot D, Zalcman G, Barlesi F.

Eur Respir J. 2017 Aug 10;50(2). pii: 1700514. doi: 10.1183/13993003.00514-2017. Print 2017 Aug.

11.

Lymphoproliferative Disorders of the Lung.

Borie R, Wislez M, Antoine M, Cadranel J.

Respiration. 2017;94(2):157-175. doi: 10.1159/000477740. Epub 2017 Jun 14.

PMID:
28609772
12.

Lepidic predominant adenocarcinoma and invasive mucinous adenocarcinoma of the lung exhibit specific mucin expression in relation with oncogenic drivers.

Duruisseaux M, Antoine M, Rabbe N, Rodenas A, Mc Leer-Florin A, Lacave R, Poulot V, Duchêne B, Van Seuningen I, Cadranel J, Wislez M.

Lung Cancer. 2017 Jul;109:92-100. doi: 10.1016/j.lungcan.2017.05.007. Epub 2017 May 10.

PMID:
28577958
13.

Composite biomarkers defined by multiparametric immunofluorescence analysis identify ALK-positive adenocarcinoma as a potential target for immunotherapy.

Roussel H, De Guillebon E, Biard L, Mandavit M, Gibault L, Fabre E, Antoine M, Hofman P, Beau-Faller M, Blons H, Danel C, Barthes FLP, Gey A, Granier C, Wislez M, Laurent-Puig P, Oudard S, Bruneval P, Badoual C, Cadranel J, Tartour E.

Oncoimmunology. 2017 Feb 21;6(4):e1286437. doi: 10.1080/2162402X.2017.1286437. eCollection 2017.

14.

Intratumoural heterogeneity generated by Notch signalling promotes small-cell lung cancer.

Lim JS, Ibaseta A, Fischer MM, Cancilla B, O'Young G, Cristea S, Luca VC, Yang D, Jahchan NS, Hamard C, Antoine M, Wislez M, Kong C, Cain J, Liu YW, Kapoun AM, Garcia KC, Hoey T, Murriel CL, Sage J.

Nature. 2017 May 18;545(7654):360-364. doi: 10.1038/nature22323. Epub 2017 May 10.

15.

Molecular classification of pulmonary sarcomatoid carcinomas suggests new therapeutic opportunities.

Pécuchet N, Vieira T, Rabbe N, Antoine M, Blons H, Cadranel J, Laurent-Puig P, Wislez M.

Ann Oncol. 2017 Jul 1;28(7):1597-1604. doi: 10.1093/annonc/mdx162.

PMID:
28419182
16.

MET exon 14 mutations as targets in routine molecular analysis of primary sarcomatoid carcinoma of the lung.

Saffroy R, Fallet V, Girard N, Mazieres J, Sibilot DM, Lantuejoul S, Rouquette I, Thivolet-Bejui F, Vieira T, Antoine M, Cadranel J, Lemoine A, Wislez M.

Oncotarget. 2017 Jun 27;8(26):42428-42437. doi: 10.18632/oncotarget.16403.

17.

Women Epidemiology Lung Cancer (WELCA) study: reproductive, hormonal, occupational risk factors and biobank.

Stücker I, Martin D, Neri M, Laurent-Puig P, Blons H, Antoine M, Guiochon-Mantel A, Brailly-Tabard S, Canonico M, Wislez M, Trédaniel J; WELCA study group.

BMC Public Health. 2017 Apr 17;17(1):324. doi: 10.1186/s12889-017-4191-1.

18.

Exon 14 Deleted MET Receptor as a New Biomarker and Target in Cancers.

Cortot AB, Kherrouche Z, Descarpentries C, Wislez M, Baldacci S, Furlan A, Tulasne D.

J Natl Cancer Inst. 2017 May 1;109(5). doi: 10.1093/jnci/djw262. Review.

PMID:
28376232
19.

[Crizotinib for ROS1-rearranged non-small cell lung cancer patients].

Domblides C, Antoine M, Lavole A, Cadranel J, Wislez M.

Bull Cancer. 2017 Apr;104(4):303-310. doi: 10.1016/j.bulcan.2017.01.008. Epub 2017 Feb 22. French.

PMID:
28237354
20.

Spotlight on crizotinib in the first-line treatment of ALK-positive advanced non-small-cell lung cancer: patients selection and perspectives.

Leprieur EG, Fallet V, Cadranel J, Wislez M.

Lung Cancer (Auckl). 2016 Jun 17;7:83-90. doi: 10.2147/LCTT.S99303. eCollection 2016. Review.

21.

[Which recent results in Oncology and Hematology will have an impact on our practices? The point of vue of Bulletin du Cancer editorial board].

Vignot S, André T, Gonçalves A, Guièze R, Magné N, Orbach D, Penel N, Thariat J, Wislez M, Bay JO.

Bull Cancer. 2017 Jan;104(1):6-19. doi: 10.1016/j.bulcan.2016.11.009. Epub 2016 Dec 19. Review. French.

PMID:
28007296
22.

[Perioperative therapies in surgical non N2 non-small cell lung cancer].

Ruppert AM, Lavolé A, Assouad J, Cadranel J, Wislez M.

Bull Cancer. 2017 Jan;104(1):79-85. doi: 10.1016/j.bulcan.2016.10.017. Epub 2016 Nov 29. Review. French.

PMID:
27912893
23.

[Osimertinib (Tagrisso®): Activity, indication and modality of use in non-small cell lung cancer].

Giroux Leprieur E, Cortot AB, Cadranel J, Wislez M.

Bull Cancer. 2016 Oct;103(10):815-821. doi: 10.1016/j.bulcan.2016.06.007. Epub 2016 Sep 15. French.

PMID:
27641462
24.

[Therapeutic management of poorly differentiated neuroendocrine lung tumors and neuroendocrine carcinomas of the digestive system].

Pellat A, Wislez M, Svrcek M, Hammel P, Afchain P, André T.

Bull Cancer. 2016 Oct;103(10):880-895. doi: 10.1016/j.bulcan.2016.06.006. Epub 2016 Aug 6. French.

PMID:
27507031
25.

NRG1 fusion in a French cohort of invasive mucinous lung adenocarcinoma.

Duruisseaux M, McLeer-Florin A, Antoine M, Alavizadeh S, Poulot V, Lacave R, Rabbe N, Cadranel J, Wislez M.

Cancer Med. 2016 Dec;5(12):3579-3585. doi: 10.1002/cam4.838. Epub 2016 Oct 21.

26.

Pulmonary mucosa-associated lymphoid tissue lymphoma revisited.

Borie R, Wislez M, Antoine M, Copie-Bergman C, Thieblemont C, Cadranel J.

Eur Respir J. 2016 Oct;48(4):1252. doi: 10.1183/13993003.01143-2016. No abstract available.

PMID:
27694418
27.

Real-life effectiveness of erlotinib as second-line treatment of stage IIIB/IV squamous non-small cell lung cancer: Results of the PEPiTA observational study.

Monnet I, Audigier-Valette C, Girard N, Vergnenègre A, Molinier O, Souquet PJ, Blanchon F, Bonnetain F, Taguieva-Pioger N, Lamour C, Wislez M.

Lung Cancer. 2016 Aug;98:84-90. doi: 10.1016/j.lungcan.2016.05.016. Epub 2016 May 26.

PMID:
27393512
28.

Sarcomatoid lung carcinomas show high levels of programmed death ligand-1 (PD-L1) and strong immune-cell infiltration by TCD3 cells and macrophages.

Vieira T, Antoine M, Hamard C, Fallet V, Duruisseaux M, Rabbe N, Rodenas A, Cadranel J, Wislez M.

Lung Cancer. 2016 Aug;98:51-58. doi: 10.1016/j.lungcan.2016.05.013. Epub 2016 May 21.

29.

Nfib Promotes Metastasis through a Widespread Increase in Chromatin Accessibility.

Denny SK, Yang D, Chuang CH, Brady JJ, Lim JS, Grüner BM, Chiou SH, Schep AN, Baral J, Hamard C, Antoine M, Wislez M, Kong CS, Connolly AJ, Park KS, Sage J, Greenleaf WJ, Winslow MM.

Cell. 2016 Jul 14;166(2):328-342. doi: 10.1016/j.cell.2016.05.052. Epub 2016 Jun 30.

30.

Health-related quality of life in elderly patients with advanced non-small cell lung cancer comparing carboplatin and weekly paclitaxel doublet chemotherapy with monotherapy.

Fiteni F, Anota A, Bonnetain F, Oster JP, Pichon E, Wislez M, Dauba J, Debieuvre D, Souquet PJ, Bigay-Game L, Molinier O, Dansin E, Poudenx M, Milleron B, Morin F, Zalcman G, Quoix E, Westeel V.

Eur Respir J. 2016 Sep;48(3):861-72. doi: 10.1183/13993003.01695-2015. Epub 2016 Jun 23.

31.

Sensitivity to chemotherapy/tyrosine kinase inhibitors of mucinous lepidic adenocarcinoma should be tested in a phase III trial?

Cadranel J, Wislez M, Langlais A, Morin F, Zalcman G.

Eur Respir J. 2016 Jun;47(6):1890-1. doi: 10.1183/13993003.01936-2015. No abstract available.

32.

EGFR and KRAS mutation status in non-small-cell lung cancer occurring in HIV-infected patients.

Créquit P, Ruppert AM, Rozensztajn N, Gounant V, Vieira T, Poulot V, Antoine M, Chouaid C, Wislez M, Cadranel J, Lavole A.

Lung Cancer. 2016 Jun;96:74-7. doi: 10.1016/j.lungcan.2015.11.021. Epub 2015 Nov 28.

PMID:
27133754
33.

[MET exon 14 mutation, new target in lung sarcomatoid carcinoma].

Domblides C, Cortot A, Wislez M.

Bull Cancer. 2015 Dec;102(12):966. French. No abstract available.

PMID:
27064153
34.

Mutations at the splice sites of exon 14 of MET gene: a new target for sarcomatoid carcinomas?

Wislez M, Domblides C, Cortot A, Lemoine A.

Ann Transl Med. 2016 Mar;4(5):96. doi: 10.21037/atm.2016.01.12. No abstract available.

35.

[Crizotinib: At last in first-line treatment of advanced-stage ALK-rearranged non-small cell lung cancer].

Giroux Leprieur E, Wislez M.

Bull Cancer. 2016 Feb;103(2):125-6. doi: 10.1016/j.bulcan.2015.12.002. Epub 2016 Jan 25. French. No abstract available.

PMID:
26822904
36.

Pulmonary mucosa-associated lymphoid tissue lymphoma revisited.

Borie R, Wislez M, Antoine M, Copie-Bergman C, Thieblemont C, Cadranel J.

Eur Respir J. 2016 Apr;47(4):1244-60. doi: 10.1183/13993003.01701-2015. Epub 2016 Jan 21. Review.

37.

[2015 through the eyes of the Bulletin of Cancer editorial board].

Magné N, Massard C, Bay JO, André T, Blay JY, Goncalves A, Orbach D, Wislez M, Thariat J, Penel N, Rancoule C, Vignot S.

Bull Cancer. 2016 Jan;103(1):3-17. doi: 10.1016/j.bulcan.2015.11.006. Epub 2016 Jan 15. French.

PMID:
26782079
38.

[Pulmonary sarcomatoid carcinoma].

Antoine M, Vieira T, Fallet V, Hamard C, Duruisseaux M, Cadranel J, Wislez M.

Ann Pathol. 2016 Jan;36(1):44-54. doi: 10.1016/j.annpat.2015.11.007. Epub 2016 Jan 8. Review. French.

PMID:
26778815
39.

[News about targeted therapies in non-small-cell lung cancer in 2015 (except immuno-therapy)].

Hamard C, Ruppert AM, Lavole A, Rozensztajn N, Antoine M, Cadranel J, Wislez M.

Ann Pathol. 2016 Jan;36(1):63-72. doi: 10.1016/j.annpat.2015.11.002. Epub 2016 Jan 6. Review. French.

PMID:
26775573
40.

Sonic Hedgehog Pathway Activation Is Associated With Resistance to Platinum-Based Chemotherapy in Advanced Non-Small-Cell Lung Carcinoma.

Giroux Leprieur E, Vieira T, Antoine M, Rozensztajn N, Rabbe N, Ruppert AM, Lavole A, Cadranel J, Wislez M.

Clin Lung Cancer. 2016 Jul;17(4):301-8. doi: 10.1016/j.cllc.2015.12.007. Epub 2015 Dec 17.

PMID:
26762562
41.

[Pathological complete response: A predictive survival factor after neoadjuvant chemotherapy in lung cancer].

Milleron B, Westeel V, Gounant V, Wislez M, Quoix E.

Bull Cancer. 2016 Jan;103(1):66-72. doi: 10.1016/j.bulcan.2015.11.001. Epub 2015 Dec 9. Review. French.

PMID:
26682626
42.

Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort.

Mazières J, Barlesi F, Filleron T, Besse B, Monnet I, Beau-Faller M, Peters S, Dansin E, Früh M, Pless M, Rosell R, Wislez M, Fournel P, Westeel V, Cappuzzo F, Cortot A, Moro-Sibilot D, Milia J, Gautschi O.

Ann Oncol. 2016 Feb;27(2):281-6. doi: 10.1093/annonc/mdv573. Epub 2015 Nov 23.

PMID:
26598547
43.

[Non-small cell lung cancer: Remarkable developments].

Vignot S, Wislez M.

Bull Cancer. 2015 Dec;102(12):962-3. doi: 10.1016/j.bulcan.2015.10.008. Epub 2015 Nov 17. French. No abstract available.

PMID:
26597477
44.

[Modalities of use of ceritinib (Zykadia™), a 2nd generation ALK inhibitor, in advanced stage non-small cell lung cancer].

Giroux Leprieur E, Fallet V, Wislez M.

Bull Cancer. 2015 Dec;102(12):1053-7. doi: 10.1016/j.bulcan.2015.09.007. Epub 2015 Nov 18. Review. French.

PMID:
26597476
45.

[Nivolumab, a new hope in non-small cell lung cancer].

Flippot R, Fallet V, Besse B, Massard C, Wislez M, Vignot S.

Bull Cancer. 2015 Dec;102(12):1046-52. doi: 10.1016/j.bulcan.2015.10.005. Epub 2015 Nov 14. Review. French.

PMID:
26585939
46.

Is there a specific phenotype associated with the different subtypes of KRAS mutations in patients with advanced non-small-cell lung cancers?

Dumenil C, Vieira T, Rouleau E, Antoine M, Duruisseaux M, Poulot V, Lacave R, Cadranel J, Massiani MA, Wislez M.

Lung Cancer. 2015 Dec;90(3):561-7. doi: 10.1016/j.lungcan.2015.10.012. Epub 2015 Oct 14.

PMID:
26520186
47.

Erlotinib versus carboplatin and paclitaxel in advanced lepidic adenocarcinoma: IFCT-0504.

Cadranel J, Gervais R, Merle P, Moro-Sibilot D, Westeel V, Bigay-Game L, Quoix E, Friard S, Barlesi F, Lethrosne C, Moreau L, Monnet I, Salaun M, Oliviero G, Souquet PJ, Antoine M, Langlais A, Morin F, Wislez M, Zalcman G; Intergroupe Francophone de Cancérologie Thoracique (IFCT).

Eur Respir J. 2015 Nov;46(5):1440-50. doi: 10.1183/13993003.02358-2014. Epub 2015 Sep 17.

48.

Human RNA polymerase II associated factor 1 complex promotes tumorigenesis by activating c-MYC transcription in non-small cell lung cancer.

Zhi X, Giroux-Leprieur E, Wislez M, Hu M, Zhang Y, Shi H, Du K, Wang L.

Biochem Biophys Res Commun. 2015 Oct 2;465(4):685-90. doi: 10.1016/j.bbrc.2015.08.017. Epub 2015 Aug 15. Erratum in: Biochem Biophys Res Commun. 2015 Dec 25;468(4):934.

PMID:
26282204
49.

Crizotinib Associated with Ground-Glass Opacity Predominant Pattern Interstitial Lung Disease: A Retrospective Observational Cohort Study with a Systematic Literature Review.

Créquit P, Wislez M, Fleury Feith J, Rozensztajn N, Jabot L, Friard S, Lavole A, Gounant V, Fillon J, Antoine M, Cadranel J.

J Thorac Oncol. 2015 Aug;10(8):1148-55. doi: 10.1097/JTO.0000000000000577.

50.

High-throughput somatic mutation profiling in pulmonary sarcomatoid carcinomas using the LungCarta™ Panel: exploring therapeutic targets.

Fallet V, Saffroy R, Girard N, Mazieres J, Lantuejoul S, Vieira T, Rouquette I, Thivolet-Bejui F, Ung M, Poulot V, Schlick L, Moro-Sibilot D, Antoine M, Cadranel J, Lemoine A, Wislez M.

Ann Oncol. 2015 Aug;26(8):1748-53. doi: 10.1093/annonc/mdv232. Epub 2015 May 12.

PMID:
25969368

Supplemental Content

Loading ...
Support Center